Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer

Cancer Letters

Volumn 270, Issue 1, 2008, Pages 108-119

  Hassan, Nur Mohammad Monsur ^a   Tada, Mitsuhiro ^a   Hamada, Jun ichi ^a   Kashiwazaki, Haruhiko ^a   Kameyama, Takeshi ^a   Akhter, Rahena ^a   Yamazaki, Yutaka ^a   Yano, Masahiro ^a   Inoue, Nobuo ^a   Moriuchi, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Disease free survival; Dominant negative; Early recurrence; Oral cancer; p53 Mutation

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; ASSAY; CANCER RECURRENCE; CARCINOGENESIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DOMINANT NEGATIVE MUTATION; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TP53 GENE; TRANSCRIPTIONAL REPORTER SYSTEM; TRANSDOMINANCE ASSAY; YEAST; YEAST FUNCTIONAL ASSAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; NEOPLASM RECURRENCE, LOCAL;

EID: 50649125210     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.04.052     Document Type: Article

References (57)

1. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
2. Sakai E., and Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 7 (1992) 927-933
3. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19 (2002) 607-614
4. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer 54 (1993) 594-606
5. The American Society of Clinical Oncology, Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer, J. Clin. Oncol. 14 (1996) 2843-2877.
6. Shimada Y., Imamura M., Shibagaki I., Tanaka H., Miyahara T., Kato M., and Ishizaki K. Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann. Surg. 226 (1997) 162-168
7. Sigal A., and Rotter V. Oncogenic mutations of the tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60 (2000) 6788-6793
8. Soussi T. Analysis of p53 gene alterations in cancer: a critical view (chapter 12). In: Hainaut P. (Ed). 25 Years of p53 Research (2005), Springer-Verlag, New York 255-291
9. Varley J.M., Evans D.G., and Birch J.M. Li-Fraumeni syndrome-a molecular and clinical review. Br. J. Cancer 76 (1997) 1-14
10. Iwakuma T., Lozano G., and Flores E.R. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle 4 (2005) 865-867
11. Kashiwazaki H., Tonoki H., Tada M., Chiba I., Shindoh M., Totsuka Y., Iggo R., and Moriuchi T. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 15 (1997) 2667-2674
12. Friedman P.N., Chen X., Bargonetti J., and Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA 90 (1993) 3319-3323
13. Jeffrey P.D., Gorina S., and Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267 (1995) 1498-1502
14. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., Finlay C., and Levine A.J. Gain of function mutations in p53. Nat. Genet. 4 (1993) 42-46
15. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 (1997) 296-299
16. Midgley C.A., and Lane D.P. p53 protein stability in tumor cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15 (1997) 1179-1189
17. Peng Y., Chen L., Li C., Lu W., Agrawal S., and Chen J. Stabilization of the MDM2 oncoprotein by mutant p53. J. Biol. Chem. 276 (2001) 6874-6878
18. Agarwal S., Mathur M., Srivastava A., and Ralhan R. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. Oral Oncol. 35 (1999) 209-216
19. Marutani M., Tonoki H., Tada M., Takahashi M., Kashiwazaki H., Hida Y., Hamada J.-I., Asaka M., and Moriuchi T. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res. 59 (1999) 4765-4769
20. van Oijen M.G.C.T., and Slootweg P.J. Gain-of-function mutations in the tumor suppressor gene p53. Clin. Cancer Res. 6 (2000) 2138-2145
21. Roemer K. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Biol. Chem. 380 (1999) 879-887
22. Sakuragi N., Watari H., Ebina Y., Yamamoto R., Steiner E., Koelbl H., Yano M., Tada M., and Moriuchi T. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int. J. Cancer 11 (2005) 514-519
23. Olivier M., Langerød A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Bièche I., Varley J., Bignon Y., Uhrhammer N., Winqvist R., Jukkola-Vuorinen A., Niederacher D., Kato S., Ishioka C., Hainaut P., and Børresen-Dale A.-L. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 12 (2006) 1157-1167
24. Galmarini C.M., Kamath K., Vanier-Viornery A., Hervieu V., Peiller E., Falette N., Puisieux A., Jordan M.A., and Dumontet C. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br. J. Cancer 88 (2003) 1793-1799
25. Wong R.P.C., Tsang W.P., Chau P.Y., Co N.N., Tsang T.Y., and Kwok T.T. p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol. Cancer Ther. 6 (2007) 1054-1061
26. Yamazaki Y., Chiba I., Hirai A., Satoh C., Sakakibara N., Notani K.-I., Kashiwazaki H., Tei K., Totsuka Y., and Fukuda H. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol. 39 (2003) 163-169
27. de Vicente J.C., Gutiérrez L.M.J., Zapatero A.H., Forcelledo M.F.F., Hernández-Vallejo G., and Arranz J.S.L. Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases. Head Neck 26 (2004) 22-30
28. Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P., Sappino A.P., Limacher J.M., Bron L., Benhattar J., Tada M., Van Meir E.G., Estreicher A., and Iggo R.D. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA 92 (1995) 3963-3967
29. Sobin L.H., and Wittekind C. International Union Against Cancer, (ICD-O C02-C06) Lip and Oral Cavity. TNM classification of malignant tumours. sixth ed. (2002), Wiley Liss, New York 22-26
30. Tada M., Iggo R.D., Waridel F., Nozaki M., Matsumoto R., Sawamura Y., Shinohe Y., Ikeda J., and Abe H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol. Carcinog. 18 (1997) 171-176
31. Stotz A., and Linder P. The ADE2 gene from Saccharomyces cerevisiae: sequence and new vectors. Gene 95 (1990) 91-98
32. van Houten V.M.M., Tabor M.P., van den Brekel M.W.M., Dekers F., Wishaupt R.G.A., Kummer J.A., Snow G.B., and Brakenhoff R.H. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin. Cancer Res. 6 (2000) 3803-3816
33. Bosch F.X., Ritter D., Enders C., Flechtenmacher C., Abel U., Dietz A., Hergenhahn M., and Weidauer H. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int. J. Cancer 11 (2004) 530-538
34. Yao L., Iwai M., and Furuta I. Correlation of bcl2 and p53 expression with the clinico-pathological features in tongue squamous cell carcinomas. Oral Oncol. 35 (1999) 56-62
35. Sanderson R.J., and Ironside J.A.D. Squamous cell carcinomas of the head and neck. Br. Med. J. 325 (2002) 822-827
36. Ruokolainen H., Paako P., and Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin. Cancer Res. 11 (2005) 3257-3264
37. Leemans C.R., Tiwari R., Nauta J.J., van der Waal I., and Snow G.B. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71 (1993) 452-456
38. Yamazaki Y., Chiba I., Hirai A., Satoh C., Sakakibara N., Notani K.-I., Lizuka T., and Totsuka Y. Clinical value of genetically diagnosed lymph node micrometastasis for patients with oral squamous cell carcinoma. Head Neck 27 (2005) 676-681
39. Wang J.-Y., Lin S.-R., Wu D.-C., Lu C.-Y., Yu F.-J., Hsieh J.-S., Cheng T.-L., Koay L.-B., and Uen Y.-H. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin. Cancer Res. 13 (2007) 2406-2413
40. Klein C.A., Blankenstein T.J.F., Schmidt-Kittler O., Petronio M., Polzer B., Stoecklein N.H., Polzer B., Stoecklein N.H., and Riethmüller G. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360 (2002) 683-689
41. Lindemann F., Schlimok G., Dirschedl P., Witte J., and Riethmüller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340 (1992) 685-689
42. Pantel K., Izbicki J., Passlick B., Angstwurm M., Häussinger K., Thetter O., and Riethmüller G. Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347 (1996) 649-653
43. Thorban S., Rosenberg R., Busch R., and Roder R.J. Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. Br. J. Cancer 83 (2000) 35-39
44. Braun S., Pantel K., Müller P., Janni W., Hepp F., Kentenich C.R.M., Gastroph S., Wischnik A., Dimpfl T., Kinderman G., Riethmüller G., and Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342 (2000) 525-533
45. Weckermann D., Müller P., Wawroschek F., Harzmann R., Riethmüller G., and Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer detection and prognostic value. J. Urol. 166 (2001) 699-703
46. Petitjean A., Achatz M.I.W., Borresen-Dale A.-L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
47. Aurelio O.N., Kong X.-T., Gupta S., and Stanbridge E.J. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol. 20 (2000) 770-778
48. Willis A., Jung E.J., Wakefield T., and Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23 (2004) 2330-2338
49. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3 (2003) 155-168
50. Jin S., Tong T., Fan W., Fan F., Antinore M.J., Zhu X., Mazzacurati L., Li X., Petrik K.L., Rajasekaran B., Wu M., and Zhan Q. GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene 21 (2002) 8696-8704
51. Strano S., Munarriz E., Rossi M., Castagnoli L., Shaul Y., Sacchi A., Oren M., Sudol M., Cesareni G., and Blandino G. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J. Biol. Chem. 276 (2001) 15164-15173
52. Kim E., and Deppert W. Transcriptional activities of mutant p53: when mutations are more than a loss. J. Cell. Biochem. 93 (2004) 878-886
53. Scian M.J., Stagliano K.E.R., Ellis M.A., Hassan S., Bowman M., Miles M.F., Deb S.P., and Deb S. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res. 64 (2004) 7447-7454
54. Lang G.A., Iwakuma T., Suh Y.-A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., El-Naggar A.K., and Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119 (2004) 861-872
55. Weisz L., Zalcenstein A., Stambolsky P., Cohen Y., Goldfinger N., Oren M., and Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res. 64 (2004) 8318-8327
56. Song H., Hollstein M., and Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 9 (2007) 573-580
57. Shaha A.R. Neck dissection: an operation in evolution. World J. Surg. Oncol. 3 (2005) 22-24